Publicacións en colaboración con investigadores/as de Hospital Universitario La Fe (4)

2022

  1. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Characterization of new proteomic biomarker candidates in mucopolysaccharidosis type IVA

    International Journal of Molecular Sciences, Vol. 22, Núm. 1, pp. 1-22

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170

2011

  1. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of seattle heart failure score

    American Journal of Cardiology, Vol. 107, Núm. 6, pp. 938-944